Biosimilars – Market Events And Forecast – Overview Of Biosimilars Forecasts

In 2019, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in these same therapy areas totaled approximately $8.5 billion. Throughout our 2019-2029 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.

Table of contents

  • Biosimilars - Market Events And Forecast - Overview Of Biosimilars Forecasts
    • Overview of Biosimilar Forecasts
      • Key Drivers and Barriers to Biosimilars in the Major Markets
      • Total Major-Market Reference Brand and Biosimilar Market Shares: 2029
      • Total Major-Market Reference Brand and Biosimilar Market Shares
      • Biosimilar Erosion
        • Example of the Erosion of Biologics' Uptake by Biosimilar Competition
    • Biosimilar Erosion in the Major Markets
      • Biosimilar Erosion in the Major Markets: 2019, 2024, 2029
      • Total Major-Market Reference-Brand and Biosimilar Sales: 2019-2029
      • Definitions
      • Biosimilar and Reference-Brand Sales and Total Market Savings in the Major Markets: 2019-2029
      • U.S. Sales of Reference Brands and Biosimilars: 2019-2029
      • Order of Biosimilar Entry: United States
      • EU5 Sales of Reference Brands and Biosimilars: 2019-2029
      • Order of Biosimilar Entry: EU5
      • Japanese Sales of Reference Brands and Biosimilars: 2019-2029
      • Order of Biosimilar Entry: Japan
      • Major-Market Sales of Reference Brands and Biosimilars: 2019-2029
      • Sales Erosion of Major-Market Reference Brands: 2019-2029
      • Major-Market Share of Biosimilars by Region: 2019-2029
      • Major-Market Shares of Biosimilars by Class: 2019-2029

launch Related Market Assessment Reports